Rock Point Advisors’s Pfizer PFE Stock Holding History

Rock Point Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.77M	Sell	114,885 -800	-0.7%	-$20.9K	0.68%	47
2026 Q1	$3.25M	Sell	115,685 -148	-0.1%	-$3.94K	0.88%	42
2025 Q4	$2.88M	Sell	115,833 -7,834	-6%	-$198K	0.72%	44
2025 Q3	$3.15M	Buy	123,667 +29,658	+32%	+$732K	0.84%	41
2025 Q2	$2.28M	Buy	94,009 +2,217	+2%	+$51.7K	0.64%	45
2025 Q1	$2.33M	Buy	91,792 +1,190	+1%	+$31.1K	0.72%	43
2024 Q4	$2.4M	Sell	90,602 -1,168	-1%	-$31.7K	0.7%	43
2024 Q3	$2.66M	Buy	91,770 +360	+0.4%	+$10.5K	0.73%	44
2024 Q2	$2.56M	Sell	91,410 -843	-0.9%	-$23.2K	0.77%	44
2024 Q1	$2.56M	Buy	92,253 +12,575	+16%	+$349K	0.76%	45
2023 Q4	$2.29M	Sell	79,678 -5,237	-6%	-$158K	0.7%	44
2023 Q3	$2.82M	Buy	84,915 +7,447	+10%	+$263K	0.97%	39
2023 Q2	$2.84M	Buy	77,468 +2,110	+3%	+$82.1K	0.93%	43
2023 Q1	$3.08M	Buy	75,358 +4,358	+6%	+$188K	1.05%	38
2022 Q4	$3.64M	Sell	71,000 -1,238	-2%	-$59.4K	1.26%	34
2022 Q3	$3.16M	Sell	72,238 -639	-0.9%	-$31.1K	1.18%	32
2022 Q2	$3.82M	Sell	72,877 -10,232	-12%	-$521K	1.3%	35
2022 Q1	$4.3M	Sell	83,109 -6,918	-8%	-$359K	1.28%	34
2021 Q4	$5.32M	Sell	90,027 -1,910	-2%	-$94.6K	1.5%	32
2021 Q3	$3.95M	Sell	91,937 -4,621	-5%	-$205K	1.16%	40
2021 Q2	$3.78M	Sell	96,558 -6,718	-7%	-$261K	1.09%	35
2021 Q1	$3.74M	Buy	103,276 +20,172	+24%	+$716K	1.17%	33
2020 Q4	$3.06M	Buy	83,104 +68,765	+480%	+$2.52M	1.05%	35
2020 Q3	$499K	Sell	14,339 -2,809	-16%	-$98.5K	0.22%	50
2020 Q2	$532K	Sell	17,148 -368	-2%	-$12.5K	0.25%	48
2020 Q1	$542K	Hold	17,516	–	–	0.32%	45
2019 Q4	$651K	Sell	17,516 -27	-0.2%	-$962	0.26%	42
2019 Q3	$598K	Buy	17,543 +167	+1%	+$6.07K	0.27%	36
2019 Q2	$714K	Sell	17,376 -612	-3%	-$24.3K	0.32%	35
2019 Q1	$725K	Sell	17,988 -2,108	-10%	-$84.4K	0.34%	35
2018 Q4	$832K	Sell	20,096 -105	-0.5%	-$4.36K	0.43%	36
2018 Q3	$845K	Sell	20,201 -1,660	-8%	-$63.9K	0.38%	35
2018 Q2	$752K	Buy	21,861 +258	+1%	+$8.82K	0.35%	37
2018 Q1	$727K	Sell	21,603 -358	-2%	-$12.3K	0.36%	38
2017 Q4	$755K	Sell	21,961 -731	-3%	-$24.9K	0.35%	37
2017 Q3	$769K	Buy	22,692 +106	+0.5%	+$3.41K	0.36%	41
2017 Q2	$720K	Hold	22,586	–	–	0.34%	42
2017 Q1	$733K	Sell	22,586 -269	-1%	-$8.48K	0.37%	42
2016 Q4	$704K	Sell	22,855 -26	-0.1%	-$794	0.36%	46
2016 Q3	$735K	Sell	22,881 -369	-2%	-$12.3K	0.38%	44
2016 Q2	$777K	Hold	23,250	–	–	0.42%	45
2016 Q1	$654K	Buy	23,250 +516	+2%	+$14.7K	0.35%	46
2015 Q4	$696K	Sell	22,734 -131	-0.6%	-$4.12K	0.36%	46
2015 Q3	$681K	Sell	22,865 -221	-1%	-$7.09K	0.37%	46
2015 Q2	$734K	Sell	23,086 -700	-3%	-$22.8K	0.38%	46
2015 Q1	$785K	Sell	23,786 -711	-3%	-$22.6K	0.39%	45
2014 Q4	$724K	Sell	24,497 -105	-0.4%	-$3.01K	0.33%	47
2014 Q3	$690K	Hold	24,602	–	–	0.33%	45
2014 Q2	$693K	Buy	24,602 +167	+0.7%	+$4.76K	0.3%	45
2014 Q1	$745K	Buy	24,435 +6,577	+37%	+$196K	0.33%	47
2013 Q4	$519K	Buy	17,858 +5,184	+41%	+$151K	0.23%	50
2013 Q3	$345K	Hold	12,674	–	–	0.16%	57
2013 Q2	$337K	Buy	+12,674	New	+$350K	0.17%	56

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Rock Point Advisors's PFE Position: Q2 2026 in Review

Rock Point Advisors reduced its Pfizer (PFE) stake by 0.69% in Q2 2026, selling an estimated $20.9K and leaving 114,885 shares worth $2.77M. The position accounts for 0.68% of the portfolio, ranked #47.

Rock Point Advisors first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $5.32M in Q4 2021. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Rock Point Advisors held 114,885 shares of Pfizer worth $2.77M as of Q2 2026.
Rock Point Advisors sold 800 Pfizer shares in Q2 2026, an estimated $20.9K.
Pfizer made up 0.68% of Rock Point Advisors's portfolio in Q2 2026, its #47 holding.
Rock Point Advisors first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
Rock Point Advisors's Pfizer position peaked at $5.32M in Q4 2021.
2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Rock Point Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.